Heather Knowles
Acute Care · Mount Vernon, ILNPI 1922244045
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,656 of the $6,421 with a category attached, or 72.5%. It is spread thinly across 34 manufacturers, the largest accounting for just 20.2%. 2025 is the largest year on record at $2,300, 2.2 times the $1,035 reported in 2021. Among acute care clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 262 payments — averaging $24.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Autolus Inc$1K
- Astellas Pharma US Inc$828
- Johnson & Johnson$816
- AbbVie$351
- Sumitomo Pharma America, Inc.$345
- Endo Pharmaceuticals Inc.$343
- plus $2K from 28 others
What the payments were for
- Speaking & faculty fees$1,29520%
- Food & beverage$4,65673%
- Education$4707%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Autolus Inc | 1 | $1,295 |
| Astellas Pharma US Inc | 32 | $828 |
| Johnson & Johnson | 38 | $816 |
| AbbVie(2 entities) | 20 | $351 |
| Sumitomo Pharma America, Inc. | 21 | $345 |
| Endo Pharmaceuticals Inc. | 17 | $343 |
| Pfizer | 18 | $330 |
| Bayer | 15 | $269 |
| Myriad Genetic Laboratories, Inc. | 8 | $181 |
| Urovant Sciences Inc | 13 | $159 |
| Acerus Pharmaceuticals Corporation | 8 | $138 |
| Tolmar, Inc. | 7 | $138 |
| Novartis | 6 | $132 |
| Rochester Medical Corporation | 5 | $113 |
| Merck | 6 | $103 |
| Myovant Sciences Inc. | 6 | $100 |
| Endo USA, Inc. | 5 | $98 |
| Alnylam Pharmaceuticals Inc. | 5 | $92 |
| Amgen | 5 | $84 |
| Urogen Pharma, Inc. | 4 | $75 |
| Ferring Pharmaceuticals Inc. | 3 | $72 |
| Olympus America Inc. | 3 | $63 |
| Aytu Biopharma, Inc. | 3 | $49 |
| Progenics Pharmaceuticals, Inc. | 2 | $45 |
| Teleflex LLC | 2 | $30 |
| Sanofi | 1 | $25 |
| Boston Scientific | 1 | $21 |
| Coloplast | 1 | $21 |
| Calyxo, Inc. | 1 | $20 |
| Photocure Inc | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| ABC Home Medical Supply, Inc. | 1 | $18 |
| Laborie Medical Technologies Corp. | 1 | $17 |
| Antares Pharma, Inc. | 1 | $14 |
How this compares
$6,421 in reported general payments places this provider in the 95th percentile of 461 acute care providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 154 | $129,745 |
| MyrbetriqMirabegron | 83 | $70,969 |
| Solifenacin Succinate | 231 | $10,573 |
| Estradiol | 105 | $7,988 |
| Tamsulosin Hcl | 397 | $6,915 |
| Finasteride | 287 | $3,877 |
| Darifenacin ErDarifenacin Hydrobromide | 12 | $3,191 |
| Silodosin | 52 | $3,113 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 74 | $2,305 |
| Cephalexin | 192 | $1,718 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 75 | $1,265 |
| Tolterodine Tartrate | 19 | $1,195 |
| Potassium Citrate ErPotassium Citrate | 11 | $1,169 |
| CefuroximeCefuroxime Axetil | 40 | $1,110 |
| Methenamine Hippurate | 14 | $1,041 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $345 | $129,745154 claims |
| Astellas Pharma US IncMyrbetriq | $828 | $70,96983 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 461 acute care providers in Illinois.
Other acute care in Mount Vernon
- Cristina MyersMount Vernon$2K
- Tedra GrayChicago$78K
- Lynn HickmanArlington Heights$61K
- Gwen CassidyChicago$46K
- Laura CoyleOak Lawn$34K
- Erin DarguzasChicago$17K
- Amy BatesQuincy$14K
- Sarah MiyataChicago$11K
- Katie MeadorChicago$10K
- Dena PelletreauArlington Heights$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.